A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
Recruiting · NCT07544862 · Observational (researchers observe without assigning treatment) · Lead sponsor: Chengdu Kangnuoxing Biopharma,Inc.
View the official record on ClinicalTrials.gov →Interventions studied
Stapokibart
What this trial is about
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Trial participants aged 18 years or older at baseline, with no restrictions on gender.
- Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.
Exclusion criteria
- Known history of allergic reaction to Stapokibart Injection.
- Trial participants currently or plan participating in any interventional clinical trial.
- Trial participants with hematologic malignancies.
- Women with pregnant.
- Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study.
Where it is running
1 location listed.
- Peking University People's Hospital - Beijing, Beijing Municipality, China